Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Revenue (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Revenue for 12 consecutive years, with $78000.0 as the latest value for Q1 2026.

  • For Q1 2026, Revenue fell 92.91% year-over-year to $78000.0; the TTM value through Mar 2026 reached -$920000.0, down 102.76%, while the annual FY2025 figure was $400000.0, 98.95% down from the prior year.
  • Revenue hit $78000.0 in Q1 2026 for Cartesian Therapeutics, up from -$1.4 million in the prior quarter.
  • Across five years, Revenue topped out at $39.3 million in Q2 2022 and bottomed at -$1.4 million in Q4 2025.
  • Average Revenue over 5 years is $10.9 million, with a median of $5.9 million recorded in 2023.
  • On a YoY basis, Revenue climbed as much as 533.85% in 2024 and fell as far as 116.9% in 2024.
  • Cartesian Therapeutics' Revenue stood at $16.8 million in 2022, then crashed by 50.78% to $8.3 million in 2023, then plummeted by 116.9% to -$1.4 million in 2024, then decreased by 3.79% to -$1.4 million in 2025, then surged by 105.38% to $78000.0 in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $78000.0, -$1.4 million, and $452000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.